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High expression and/or activity of calpain proteases has been associated 
with the development of fibrosis, but a mechanistic explanation of their role in this 
process remains to be defined. In this work, we show that calpain-dependent 
proteolysis is required for Transforming Growth Factor β (TGFβ)-induced 
Epithelial-to-Mesenchymal Transition (EMT), Endothelial-to-Mesenchymal 
Transition (EnMT), and Fibroblast-to-Myofibroblast Transition (FMT). These 
related cellular processes promote the generation of myofibroblasts, a cell type 
that has been strongly implicated in driving fibrosis. We show that broad-
spectrum calpain inhibitors can suppress EMT or FMT without affecting early 
TGFβ signaling events, such as phosphorylation of SMAD2. Importantly, calpain 
activity was also required for maintenance of an established myofibroblast fate. 
Overexpression of the endogenous dimeric calpain inhibitor, calpastatin, also 
potently suppressed TGFβ1-induced EMT. RNA interference (RNAi)-mediated 
knockdown of individual dimeric calpain isoforms, during TGFβ1-induced EMT, 
showed that only inhibition of CAPN9 or CAPNS2 could suppress generation of 
myofibroblasts. In epithelial cells, CAPN9 and CAPNS2 were expressed only 
under high TGFβ signaling conditions. Current data suggests that CAPN9 and 
CAPNS2 can form a heterodimer, whose activity we hypothesize is necessary for 
TGFβ-induced mesenchymal transition. We go on to show that expression of 
CAPN9 is also necessary for TGFβ1-induced cleavage of calcineurin, a known 
activator of FMT (Davis 2012). In mice, intratracheal delivery of siRNA targeting 
Capns2 or knockout of Capn9 was able to ameliorate bleomycin-induced lung 
 iii 
fibrosis. These data suggest that the selective targeting of the CAPN9/CAPNS2 
heterodimer may be a powerful therapeutic strategy for the treatment of fibrotic 
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Fibrosis is a pathologic process characterized by increased extracellular 
matrix protein synthesis and deposition, resulting in the accumulation of scar 
tissue that progressively compromises physiologic organ function. Fibrotic 
diseases are currently a leading cause of mortality in the world and are often 
associated with a poor prognosis due to limited treatment options (Coultas, 
Zumwalt et al. 1994, Perez, Rogers et al. 2003). The etiologies of common 
fibrotic diseases such as autoimmune scleroderma, idiopathic pulmonary fibrosis, 
liver cirrhosis, and kidney fibrosis remain poorly understood, thus hindering the 
development of effective therapies. The current standard of care for patients with 
scleroderma involves suppression of the immune system and management of 
symptoms, such as constriction of blood flow (Raynaud’s phenomenon) and 
joint/chest pain. These interventions, however, fail to halt or reverse pernicious 
organ fibrosis and, most importantly, fail to ameliorate the progressive pulmonary 
fibrosis most often associated with mortality. A comprehensive therapy for these 
fibrotic diseases must halt the progression of and/or reverse organ fibrosis in 
order to significantly improve patient outcomes. 
In the past decade, numerous studies have linked increased calpain 
expression and/or activity to the development of tissue fibrosis, but an underlying 
molecular mechanism has yet to be defined. Calpains are Ca2+-dependent non-
lysosomal cysteine proteases that specifically cleave their target substrate based 
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on protein tertiary structure, usually leaving an intact functional domain that 
shows an alteration and often gain of activity upon the calpain-induced post-
translational modification (Goll, Thompson et al. 2003). Calpain-mediated 
proteolysis is responsible for a wide array of functions within the cell, including 
remodeling of the cytoskeleton during cell migration (Dourdin, Bhatt et al. 2001)), 
cell cycle progression (Janossy, Ubezio et al. 2004), and apoptosis (Momeni 
2011). 
Suppression of calpain activity in mouse models has been shown to 
ameliorate thioacetamine-induced liver fibrosis (Wang, Chen et al. 2004), 
cardiovascular fibrosis after angiotensin II-infusion (Letavernier, Perez et al. 
2008), bleomycin-induced pulmonary fibrosis (Tabata, Tabata et al. 2010)), 
hypoxia/monocrotaline-induced lung fibrosis (Ma, Han et al. 2011), and scar 
formation during wound healing (Nassar, Letavernier et al. 2012). In addition, 
studies have correlated calpain expression with cancer metastasis and poor 
outcome in patients with a variety of tumors of epithelial origin (Storr, Lee et al. 
2012, Storr, Zaitoun et al. 2012, Storr, Pu et al. 2013). An in-depth understanding 
of the underlying mechanism behind this phenomenon has the potential to 
significantly contribute to the development of therapeutic agents against a 
pervasive pathologic mechanism that is relevant to diverse and common human 
disease phenotypes.  
We hypothesized that the role that calpain activity plays in both fibrosis 
and in the development of epithelial tumor metastasis could be explained by its 
involvement in a cellular process known as Epithelial-to-Mesenchymal Transition 
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(EMT). While there is controversy (and likely heterogeneity) regarding the cell 
type of origin, the concept that most if not all fibrotic disease requires 
Transforming Growth Factor β (TGFβ)-induced mesenchymal transition into 
collagen-expressing myofibroblasts has been widely accepted (Leask and 
Abraham 2004, Wynn 2007). Likewise, mesenchymal transition of epithelial 
tumors is thought to be a prerequisite for local invasion and ultimate 
dissemination of cancer cells, with a prominent contribution from enhanced 
expression and activity of matrix metalloproteinases (MMPs) (Radisky and 
Radisky 2010, Nistico, Bissell et al. 2012). In breast cancer, stromal cells 
synthesize several isoforms of MMPs, but the tumor cells produce the majority of 
MMP-9, whose expression was found to promote metastasis in a mouse 
orthotopic model (Mehner, Hockla et al. 2014). An emerging model suggests that 
cancer cells can undergo EMT to become cancer stem cells (Mani, Guo et al. 
2008, Shuang, Wu et al. 2014), gaining the ability for self-renewal and ability to 
resist chemotherapy (Pattabiraman and Weinberg 2014). Therapies designed to 
specifically target cancer stem cells have focused on inhibition of focal adhesion 
kinase or phosphoinositide 3-kinase/mammalian target of rapamycin, and are 
currently in clinical trials (Hart, Novotny-Diermayr et al. 2013, Shapiro, Kolev et 
al. 2014, Kolev, Wright et al. 2015). 
The calpain superfamily currently consists of 14 known isoforms in 
mammals that are either ubiquitous or show restricted temporal and/or spatial 
expression. Identification of subsequent isoforms was based on sequence 
homology to domain II of calpain (first half of protease domain) exceeding 20-
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25% (Goll, Thompson et al. 2003). The overwhelming majority of research has 
focused on the ubiquitously expressed calpain 1 (CAPN1 a.k.a. m-calpain), which 
requires micromolar Ca2+ concentrations for activity (determined in cell free 
systems), or calpain 2 (CAPN2 a.k.a. m-calpain), which requires millimolar levels 
of Ca2+. These high concentrations of Ca2+ are far above those present in a cell, 
which has led to several hypotheses to explain how the requirement level is 
either lowered or achieved, which remain unproven. CAPN1 and CAPN2 must 
heterodimerize with a small regulatory subunit, such as the ubiquitously 
expressed calpain small subunit 1 (CAPNS1 a.k.a. CAPN4), in order activate 
their catalytic protease activity. CAPN9 is the only other isoform that has been 
experimentally confirmed to heterodimerize with CAPNS1 (Ravulapalli, Campbell 
et al. 2009). Expression of CAPN9 is restricted to the gastrointestinal tract under 
physiological conditions (Hata, Abe et al. 2010) 
A recently identified small subunit isoform, calpain small subunit 2 
(CAPNS2), was experimentally proven to bind CAPN2 (Schad, Farkas et al. 
2002), and described to be functionally similar to CAPNS1, inferring it can bind 
CAPN1 and CAPN9 as well. In contrast to the ubiquitously expressed CAPNS1, 
CAPNS2 showed highly restricted tissue-specific expression (Ma, Nakajima et al. 
2004). The collective activity of these calpain heterodimers is regulated by the 
highly specific, potent and ubiquitously expressed endogenous calpain inhibitor 
calpastatin (Todd, Moore et al. 2003, Hanna, Campbell et al. 2008). Calpains 
cleave calpastatin – defining a mutually antagonistic relationship – but in most 
cases calpastatin activity dominates within the cell or tissue (Goll, Thompson et 
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al. 2003). The precise role of the activity of specific calpains has proven difficult 
to define with precision due to the existence of multiple isoforms and limitations 
of currently available inhibitors.  
The characterization of various genetic knockout models has greatly 
added to our understanding of the biological role of this proteolytic system. 
Capn1−/− mice exhibited decreased platelet aggregation and diminished blood 
clot retraction, but this deficiency did not result in a clinically-relevant bleeding 
diathesis (Azam, Andrabi et al. 2001), a finding that is not attributable to 
redundancy by Capn2 since it is not expressed in human platelets (Taylor, 
Christiansen et al. 1991). In contrast, Capn2−/− mice showed embryonic lethality, 
but a conditional knockout with preserved CAPN2 expression in the placenta has 
been shown to be viable suggesting an essential role in placental development 
and/or function (Takano, Mihira et al. 2011).  
Homozygous, but not heterozygous, deletion of the Capns1 gene in mice 
abrogated CAPN1 and CAPN2 protease activity in embryonic stem cells, and led 
to embryonic lethality due to impaired cardiovascular development (Arthur, Elce 
et al. 2000). Capns1+/− derived embryonic stem cells showed CAPN1 and CAPN2 
protease activity indistinguishable from wild-type, and animals appeared 
phenotypically normal (Arthur, Elce et al. 2000). Capn9−/− mice displayed an 
increased susceptibility to ethanol-induced gastritis, but no other discernible 
phenotypes were observed (Hata, Abe et al. 2010).  
Constitutive overexpression (under the control of a prion protein promoter) 
of the human calpastatin gene (CAST) in mice, resulted in decreased cleavage of 
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spectrin (a known calpain substrate) after brain injury, but no overt clinical 
phenotype (Schoch, von Reyn et al. 2013). The mild phenotype of these 
calpastatin-overexpressing mice is not surprising since during physiological 
conditions, calpastatin restrains but does not abrogate calpain activity (Goll, 
Thompson et al. 2003). Similarly, Cast−/− mice showed increased cleavage of 
spectrin in the hippocampus after injection of kainite (an inducer of excitotoxicity) 
and exhibited a decreased acoustic startle response, but were otherwise normal 
(Takano, Tomioka et al. 2005, Nakajima, Takao et al. 2008). The lack of a more 
overt phenotype could be explained by the redundant action of a similarly 
functioning calpastatin-like protein (such as high molecular weight calmodulin-
binding protein (Kakkar, Raju et al. 1997, Singh, Shrivastav et al. 2008) and/or 
absence of a strong calpain-activating stimulus (such as ischemia-reperfusion 
injury).  
In humans, three unrelated families were found to carry rare homozygous 
loss-of-function mutations in CAST that co-segregated with a disease phenotype 
characterized by skin blistering, dryness, scaling and peeling in association with, 
leukonchia (white discoloration of the nails), acral punctate keratosis (keratin 
buildup on body protrusions), angular cheilitis (inflammation of the corners of 
mouth), and knuckle pads (fibrous overgrowths over interphalangeal joints), 
collectively referred to as PLACK syndrome (Lin, Zhao et al. 2015). The disparity 
between the mild mouse and the severe human loss-of-function phenotypes 
appears difficult to reconcile, but might be explained by some residual calpastatin 
message, protein and activity in the targeted mouse line (Takano, Tomioka et al. 
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2005). Hyperactivity of calpains in humans has been associated with Alzheimer’s 
disease (Nixon 1989), enhanced ischemia-reperfusion injury (Yoshida, Yamasaki 
et al. 1993), traumatic brain injury (Arrigoni and Cohadon 1991), cataract 
formation (Hightower, David et al. 1987) and cancer (Storr, Carragher et al. 
2011). While calpain inhibitors have been proposed to treat these conditions 
(Carragher 2006, Bralic, Stemberga et al. 2012, Parameswaran and Sharma 
2012), this class of inhibitors remains at the pre-clinical or early clinical stage of 
development. 
This thesis establishes an obligate mechanistic connection between the 
activity of specific calpains and TGFβ-induced EMT and offers novel therapeutic 
















 Epithelial-to-Mesenchymal Transition (EMT) is an inducible process that 
fundamentally alters cellular identity and behavior. EMT was first discovered as a 
process by which cell type diversity is established during gastrulation (Greenburg 
and Hay 1982, Hay 1982, Hay 1995). EMT that occurs in the context of normal 
embryo development has recently been categorized as Type I EMT (Kalluri and 
Weinberg 2009). EMT is also essential to drive the production of collagen-
producing myofibroblasts in the wound healing process (Estes, Vande Berg et al. 
1994)  referred to as Type II EMT 2009 (Kalluri and Weinberg 2009). Finally, 
EMT appears critical to epithelial cancer metastasis in experimental systems 
(Ruiz and Gunthert 1996); while a direct human clinical correlate has yet to be 
found (Chui 2013), so-called type III EMT (Kalluri and Weinberg 2009) continues 
to be a major focus of cancer research (Ginnebaugh, Ahmad et al. 2014).  
 Epithelial cells are stationary by nature, tend to form large sheets with a 
cobblestone appearance in culture, are characterized by their strong cell-cell 
adhesions due to high E-cadherin expression, and have a cortical distribution of 
F-actin. In contrast, cells that have undergone EMT to become myofibroblasts 
lose their cell-cell adhesions due to loss of E-cadherin expression, are 
invasive/motile, form F-actin stress fibers, secrete large amounts of extracellular 
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matrix proteins/matrix degrading enzymes, and display spindle shaped 
morphology. Myofibroblasts are generally identified by their expression of alpha 
smooth muscle actin (αSMA), a mesenchymal protein marker. 
Although several stimuli are known to induce EMT, most act through a 
limited number of overlapping pathways (Derynck, Muthusamy et al. 2014), 
which converge on activation of a group of master transcription factors (e.g. 
Snail, Slug, Zeb, and Twist) that repress expression of epithelial proteins or 
induce expression of mesenchymal proteins (Savagner, Yamada et al. 1997, 
Guaita, Puig et al. 2002, Zuniga, Quillet et al. 2002)  
Hepatocyte growth factor was the first soluble protein found capable of 
inducing EMT (Stoker and Perryman 1985), a finding later generalized to other 
activators of receptor tyrosine kinases (Savagner, Yamada et al. 1997) including 
epithelial growth factor (Lu, Ghosh et al. 2003, Lo, Hsu et al. 2007, Zhang, Dong 
et al. 2014) and fibroblast growth factor (Valles, Boyer et al. 1990, Valles, Boyer 
et al. 1996, Billottet, Tuefferd et al. 2008). WNT signaling (Song, Zheng et al. 
2015, Yang, Sun et al. 2015) and hedgehog signaling (Yamamichi, Shigemura et 
al. 2014, Ke, Caiping et al. 2015) have also been shown to activate EMT. 
Inhibition of WNT signaling using a monoclonal antibody (OMP-18R5) was able 
to suppress type III EMT in mice with human tumor xenografts, and is currently in 
clinical trials along with other similarly acting drugs (Gurney, Axelrod et al. 2012). 
TGFβ stands out as one of the most potent, widely applicable, and consistent 
inducers of EMT in vitro, with TGFβ1 most often implicated in cancer and/or 
fibrosis in vivo (Derynck, Muthusamy et al. 2014, Gonzalez and Medici 2014, 
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Zheng and Kang 2014). For this reason, early strategies aimed at EMT inhibition 
as a treatment for cancer or fibrosis naturally focused on TGFβ inhibition 
(Yingling, Blanchard et al. 2004, Denton, Merkel et al. 2007, Connolly, Freimuth 
et al. 2012). TGFβ ligands (types 1-3) are homodimeric molecules that are 
secreted from the cell in the context of a large latent complex (LLC) that includes 
a dimer of their processed N-terminal propetide (latency-associated peptide or 
LAP) and one of three latent TGFβ binding proteins (LTBPs 1, 3 or 4). The LLC is 
sequestered within the extracellular matrix by virtue of direct biochemical 
interactions between LTBPs and structural matrix proteins (e.g. fibronectin or 
fibrillins). Latent TGFβ is converted into active TGFβ through a variety of 
mechanisms. Free TGFβ ligands bind to the type II TGFβ receptor subunit 
(TβRII), promoting the recruitment and activation (via phosphorylation) of the 
type I TGFβ receptor subunit (TβRI, a.k.a. ALK5) within the GS domain, resulting 
in a conformational change that opens up the kinase domain. The activated type 
I TGFβ receptor subunit then binds and phosphorylates receptor-activated 
SMADs (SMAD2 or SMAD3), which then partner with SMAD4, translocate to the 
nucleus and mediate transcriptional responses (in partnership with other 
transcription factors).  
Attempts have been made to inhibit the TGFβ pathway through targeting 
activators (e.g. αv integrins), ligand-receptor interactions (e.g. using neutralizing 
antibodies) or TGFβ receptor kinase activity (e.g. using small molecules). There 
has been concern that proximal inhibition may be vulnerable to pathologic 
workaround strategies (i.e. due to redundancy or compensation) and to side 
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effects that relate to loss of the pleiotropic physiologic (and beneficial) functions 
of TGFβ, prominently including wound healing, suppression of inflammation, 
tumor suppression, coordination of adaptive immunity and tissue morphogenesis. 
In light of these limitations, we have chosen to focus on a strategy aimed at 
identification of critical distal events (and hence vulnerabilities) in TGFβ-induced 
EMT. In theory, distal inhibition would preferentially target pathologic but not 
physiologic functions of TGFβ signaling. In this chapter, we asked whether 
calpain activity is required for TGFβ-induced mesenchymal transition. If 






Namru Mouse Mammary Gland Epithelial Cells (NMuMG) were obtained 
from American Type Culture Collection (CRL-1636). Cells were cultured and 
maintained in Dulbecco’s Modified Eagles Medium (DMEM), supplemented with 
10% fetal bovine serum, 2mM L-glutamine, and 10μg/mL insulin. Recombinant 
TGFβ1 was purchased from R&D Systems (240-B-010) and reconstituted in 
sterile water with 1mg/mL bovine serum albumin (BSA) and 4mM sterile cell 
culture grade hydrochloric acid purchased from Sigma (H9892). To induce EMT, 
NMuMG cells were first starved and pretreated with pharmacological inhibitors in 
0.5% serum DMEM for 24 hours, prior to treatment with TGFβ1 (5ng/mL).  
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Small Molecule Inhibitors 
MDL-28170 was purchased from Enzo Lifesciences (BML-PI130) and 
dissolved in DMSO for a 100mM stock solution. Calpeptin was purchased from 
Tocris (0448) and dissolved in DMSO for a 100mM stock solution. 2-APB was 
purchased from Sigma (D9754) and dissolved in DMSO for a 100mM stock 
solution. CA-074-OMe was purchased from Sigma (C5857) and dissolved in 
DMSO for a 100mM stock solution. SB431542 was purchased from Sigma 
(S4317) and dissolved in DMSO for a 10mM stock solution. 
 
Western Blot 
Cells were harvested from dishes/plates using radio immunoprecipitation 
assay buffer (RIPA) and sonicated. Protein concentration for samples was 
quantified by colormetric BCA Assay from Pierce (23225). Protein samples were 
prepared with Bio-Rad XT reducing agent (161-0792) and Bio-Rad XT sample 
buffer (161-0791), which was denatured at 95oC for 10 minutes. Samples were 
loaded onto Bio-Rad 10% Bis-Tris gels and separated by SDS-PAGE with MOPS 
buffer using the Bio-Rad Criterion system. Size separated proteins were 
transferred onto a methanol-activated Immobilon-FL polyvinylidene fluoride 
membrane from Millipore (IPFL00010) in 1x NuPage transfer buffer from 
Invitrogen (NP0006) with 10% methanol using the Bio-Rad Criterion Blotter with 
plate electrodes (170-3872) at 100V for 1 hour at 4°C. After protein transfer, 
membranes were blocked in Li-Cor Odyssey blocking buffer (927-40000) diluted 
1:1 with Phosphate Buffered Saline (PBS) for 1 hour with constant rocking at 
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room temperature. Membranes were probed with mouse anti-αSMA from R&D  
(Clone 1A4 MAB 1420) at 1:1000, goat anti-GAPDH from Santa Cruz 
Biotechnology (sc-20457) at 1:5000, mouse anti-phosphoSMAD2 from Millipore 
(Clone A5S 04-953) at 1:500, or rabbit anti-Filamin A-C-terminal fragment from 
Epitomics (2242-1) in diluted blocking buffer overnight with constant rocking at 
4°C. Membranes were washed for 5 minutes three times in TBS-T (1xTris 
Buffered Saline with 0.1% Tween-20), and probed with appropriate Li-Cor 
Odyssey secondary antibodies conjugated to fluorophores, for 1 hour at room 
temperature with constant rocking. Membranes were washed for 5 minutes three 
times in TBS-T and scanned using a Li-Cor Odyssey Infrared Imaging System. 
Proteins levels were quantified by measuring integrated intensity for each 
sample/lane using Odyssey Application Software 3.0. Data were processed using 
Prism 5.0. Statistics were done on each blot by normalizing to levels present at 




 NMuMG cells were plated and grown on sterilized glass coverslips. Cells 
were starved in 0.5% serum for 24 hours. Cells purposed for eventual treatment 
with MDL-28170 were pretreated with the drug, prior to treatment with TGFβ1.  
Coverslips were washed in PBS and fixed with 4% paraformaldehyde in PBS for 
10 minutes at room temperature, washed in PBS and blocked in 
immunofluorescence blocking buffer (5% Donkey Serum, 0.1% TritonX-100, in 
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PBS) for 1 hour at room temp. They were then were probed with mouse anti-E 
cadherin from BD Biosciences (610405) 1:500 in immunofluorescence blocking 
buffer overnight at 4°C. Coverslips were washed with PBS and probed with 
immunofluorescence blocking buffer containing Donkey Anti-Mouse Alexa 488 
(1:500) from Molecular Probes (A-21202), rhodamine-phalloidin (1:500) from 
Molecular Probes (R415), and DAPI (1:25000) from Molecular Probes (D1306) 
for 1 hour at room temperature in the dark. After washing with PBS, they were 
mounted on slides with Prolong Gold mounting media from Molecular Probes 
(P10144). Images were obtained using a Zeiss LSM multiphoton confocal 
microscope with 10x and 20x objective lenses.  
 
Quantitative PCR 
  RNA was harvested from cells using Qiagen RNeasy Kit (74106) with 
DNase digestion (79254). RNA was quantified by Nanodrop and used to make 
cDNA using a high capacity RNA to cDNA kit from Applied Biosystems 
(4387406). Quantitative PCR was done using TaqMan® probes for mouse 
Col1A1 (ABI Mm00801555_g1), MMP2 (ABI Mm00439498_m1), MMP9 
(Mm00442991_m1), and GAPDH (Mm99999915_g1) as a loading control 
Samples were run on a QuantStudioTM 7 Flex Real-Time PCR system. Ct values 
were corrected for loading and calculated using the 2^-ΔCt method. The average 
numerical value of the TGFβ1 only treated sample was normalized to 1 for each 
gene. P-values were calculated using Student’s t-test. 
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Results and Discussion: 
 
TGFβ1 induces EMT and increases calpain activity, events that are blocked by 
the TGFβ-receptor kinase inhibitor SB431542 
 Different epithelial cell lines show a variable propensity for TGFβ-induced 
EMT in vitro, as defined by the extent of loss of epithelial markers and gain of 
mesenchymal ones (Brown, Aakre et al. 2004).  We initially used the most robust 
and widely accepted cell line for this purpose: Namru mouse mammary gland 
(NMuMG) epithelial cells (Xie, Law et al. 2003, Brown, Aakre et al. 2004). 
 NMuMG cells treated with TGFβ1 underwent EMT, as evidenced by the 
progressive increase in expression of αSMA at 48 and 72 hours. As expected, 
this response was completely blocked upon administration of the TGFβ-receptor 
kinase inhibitor SB431542 (Figure 1). TGFβ1 treatment induced phosphorylation 
of SMAD2, an early event in the canonical (SMAD-dependent) TGFβ signaling 
cascade (Yang, Piek et al. 2003). Residual pSMAD2 induction was seen at 24, 
48 and 72 hours after treatment with TGFβ1, but was blocked by SB431542 at all 
time points.  
Treatment with TGFβ1 increased calpain proteolytic activity, as evidenced 
by increased cleavage of filamin A, a known calpain substrate (Gorlin, Yamin et 
al. 1990), which resulted in accumulation of the filamin A C-terminal cleavage 
fragment (FLNA-C; Figure 1). TGFβ1-induced filamin A cleavage was blocked by 
treatment with SB431542. Intriguing correlations between TGFβ and calpain 
activity exists in the literature (such as the fact that calpain-inhibition can 
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suppress TGFβ1-induced events like apoptosis (Gressner, Lahme et al. 1997, 
Ma, Han et al. 2011) and cell migration (Leloup, Mazeres et al. 2006). However, 
these data represent the first direct evidence for TGFβ induced calpain 
activation. They also document that in this robust culture-based assay, TGFβ-







Figure 1: Western blot-assessment of markers of TGFβ1-induced EMT and 
calpain activity in the presence of TGFβ receptor kinase inhibitor SB431542. A) 
NMuMG (epithelial) cells were treated with TGFβ1 (5ng/mL) in the presence or 
absence of SB431542 (started 24 hours prior to stimulation with TGFβ1). B) 
Results are normalized to GAPDH expression and indexed to the 72 hour TGFβ1 
alone signal (set to 1.0). Results reflect experiments performed in biological 
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Pharmacological calpain inhibitors suppress TGFβ1-induced EMT 
 MDL-28170 is a cell-permeable pharmacological calpain inhibitor within 
the peptide aldehyde class (Wang, Chen et al. 2004) and is frequently utilized for 
in vitro experiments. Like most pharmacological calpain inhibitors, it targets the 
protease active site (Lee, Morton et al. 2008). 
NMuMG cells treated with TGFβ1 and pharmacological calpain inhibitor 
MDL-28170 showed a dose-dependent inhibition of αSMA at 48 and 72 hours, 
relative to cells treated with TGFβ1 alone (Figure 2). Inhibition of calpain activity 
did not affect TGFβ1-induced phosphorylation of SMAD2, indicating that calpains 
are acting downstream of this event. The TGFβ1-mediated increase in calpain 
activity was prevented by the presence of MDL-28170, as seen by decreased 
accumulation of FLNA-C. These data provide the first indication that calpains 
played a critical role in EMT and that calpain inhibitors can block mesenchymal 
transition. These observations were also recapitulated using calpeptin 
(Tsujinaka, Kajiwara et al. 1988), another pharmacological calpain inhibitor 
(Figure 3). 
 Next we assessed the effect of pharmacological calpain inhibitors on the 
morphological changes associated with TGFβ1-induced EMT. NMuMG cells 
under steady state conditions express high levels of E-cadherin (an epithelial 
marker), localized at the cell membrane and concentrated at areas of cell-cell 
contacts (Figure 4). These cells also exhibited a cortical actin cytoskeleton 
arrangement typical of epithelial cells (Wu, Gomez et al. 2014). Treatment with 
TGFβ1 for 48 hours resulted in a dramatic downregulation of E-cadherin 
 19 
expression, a defining event in EMT. TGFβ-1 treatment also promoted the 
reorganization of cortical actin into stress fibers, which is indicative of a motile 
cellular phenotype (Tojkander, Gateva et al. 2012). Treatment with MDL-28170 
was able to suppress TGFβ1 induced E-cadherin downregulation and stress fiber 
formation. Subtle changes suggestive of altered cell morphology (increased cell 
size and flattening) were only partially inhibited by the calpain inhibitor, an 
observation that might be attributed to incomplete inhibition of EMT or to the 
possibility that some but not all TGFβ1-induced cellular events are prevented by 
the indicated doses of MDL-28170.  
We used quantitative PCR to measure mRNA levels corresponding to 
important constituents of the fibrotic synthetic repertoire of myofibroblasts. 
Treatment with TGFβ1 for 48 hours resulted in increased mRNA expression for 
Col1A1 (encoding Collagen I), Vim (encoding Vimentin), Mmp2 (encoding MMP-
2), and Mmp9 (encoding MMP-9). Calpain inhibition using MDL-28170, 



















TGFβ1 (5ng/mL) - + + + - + + + - + + +
















TGFβ1 (5ng/mL) - + + + - + + + - + + +
















TGFβ1 (5ng/mL) - + + + - + + + - + + +













Figure 2: Western blot-assessment of markers of TGFβ1-induced EMT and 
calpain activity in the presence of the pharmacological calpain inhibitor MDL-
28170. A) NMuMG (epithelial) cells were treated with TGFβ1 (5ng/mL) in the 
presence or absence of MDL-28170 (started 24 hours prior to stimulation with 
TGFβ1). B) Results are normalized to GAPDH expression and indexed to the 72 
hour TGFβ1 signal (set to 1.0). Results reflect experiments performed in 
biological triplicate. Statistics were calculated using Student’s t-test: *p<0.05 





Figure 3: Western blot-assessment for markers of TGFβ1-induced EMT and 
calpain activity in the presence of pharmacological calpain inhibitor calpeptin. A) 
NMuMG (epithelial) cells were treated with TGFβ1 (5ng/mL) in the presence or 
absence of calpeptin (started 24 hours prior to stimulation with TGFβ1). B) 
Results are normalized to GAPDH expression and indexed to the 72 hour TGFβ1 
alone signal (set to 1.0). Results reflect experiments performed in biological 
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Figure 4: Treatment with pharmacological calpain inhibitor MDL-28170 inhibits 
morphological changes associated with TGFβ1-induced EMT. A) NMuMG 
(epithelial) cells were treated with TGFβ1 (5ng/mL) for 48 hours in the presence 
or absence of MDL-28170 (started 24 hours prior to stimulation with TGFβ1). 
Cells were stained for epithelial marker E-cadherin (Green), F-actin (red), and 























































































Figure 5: Expression of TGFβ1-induced EMT-associated gene products are 
suppressed in presence of pharmacological calpain inhibitor MDL-28170. 
NMuMG (epithelial) cells were treated with TGFβ1 (5ng/mL) for 48 hours in the 
presence or absence of MDL-28170 (started 24 hours prior to stimulation with 
TGFβ1). Results are normalized to Gapdh expression and indexed to levels in 
TGFβ1 alone treated samples. Results reflect experiments performed in 
biological triplicate. Statistics were calculated using Student’s t-test: *p<0.05 








Cathepsin B inhibitor CA-074OMe has no effect on TGFβ1-induced EMT 
 Small molecule calpain inhibitors are known to partially inhibit cathepsin B 
(Neffe and Abell 2005), a calcium-independent lysososomal cysteine protease 
involved in autophagy (Uchiyama 2001). To confirm that MDL-28170/calpeptin-
mediated inhibition of EMT was selectively due to calpain-inhibition, we tested 
the effect of a methyl ester form of the specific cathepsin B inhibitor CA-074 (CA-
074OMe) on EMT. This modified from was chosen because of its improved 
cellular permeability (Buttle, Murata et al. 1992). As seen in Figure 6, addition of 
CA-074OMe at doses previously demonstrated to be potently effective at 
inhibiting cathepsin B activity in culture systems (Reich, Wieczerzak et al. 2009, 
Matarrese, Ascione et al. 2010) did not influence TGFβ1-mediated SMAD2 
phosphorylation, αSMA expression or filamin A cleavage. These data suggest 
that cathepsin B is not a critical effector of EMT, and that the EMT inhibition 















Figure 6: Western blot-assessment of markers of TGFβ1-induced EMT and 
calpain activity in the presence of cathepsin B inhibitor CA-074-OMe. A) NMuMG 
(epithelial) cells were treated with TGFβ1 (5ng/mL) in the presence or absence of 
CA-074-OMe (started 24 hours prior to stimulation with TGFβ1). B) Results are 
normalized to GAPDH expression and indexed to the 72 hour TGFβ1 alone 
signal (set to 1.0). Results reflect experiments performed in biological triplicate. 
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Ion-channel blocker 2-APB inhibits TGFβ1-induced EMT 
 The divalent cation channel TRPM7 has been reported to be particularly 
important in mediating the calcium influx required for activation of calpain activity, 
but the exact mechanism as to how this is achieved is unknown (Su, Agapito et 
al. 2006). One possibility is that calpains closely localize with specific calcium 
channels, such as TRPM7, and get exposed to the higher end of the calcium 
influx gradient. EMT induced by mechanical wounding/scratching, hypoxia or 
epidermal growth factor were shown to be mediated by transient increases in 
cytosolic calcium concentration in breast cancer cells (Davis, Azimi et al. 2014). 
This signal transduction pathway was found to be regulated by the expression of 
TRPM7. RNAi-mediated silencing of TRPM7, but not TRPV3, TRPC4, TRPC5, 
TRPC6, TRPM7, or ORAI1, prevented EGF-induction of vimentin expression in 
breast cancer cells (Davis, Azimi et al. 2014). Due to the delicate nature of 
cellular calcium homeostasis, global calpain manipulation via calcium chelators 
(EDTA) or calcium-ionophores (ionomycin) would be incompatible with long term 
experiments such as those required to assess TGFβ1-induced EMT. To assess 
for a calcium-flux dependent mechanism in TGFβ1-induced EMT (as would be 
predicted for a calpain-specific mechanism), we used 2-APB, a potent inhibitor of 
both IP3-gated and TRP channels, including TRPM7 (Su, Agapito et al. 2006). 
 Treatment with 2-APB was able to block TGFβ1-induced expression of 
αSMA in NMuMG cells (Figure 7). 2-APB did not affect TGFβ1-induced 
phosphorylation of SMAD2, as was also seen with broad-spectrum calpain 
inhibitors. TGFβ1-induced calpain activity was suppressed in the presence of 2-
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APB. These data suggest that EMT is sensitive to manipulations that restrict 
extracellular calcium influx and/or release of intracellular calcium stores, as 
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Figure 7: Western blot-assessment of markers of TGFβ1-induced EMT and 
calpain activity in the presence of ion-channel inhibitor 2-APB. A) NMuMG 
(epithelial) cells were treated with TGFβ1 (5ng/mL) in the presence or absence of 
2-APB (started 24 hours prior to stimulation with TGFβ1). B) Results are 
normalized to GAPDH expression and indexed to the 72 hour TGFβ1 alone 
signal (set to 1.0). Results reflect experiments performed in biological triplicate. 
Statistics were calculated using Student’s t-test: *p<0.05 **p<0.01 †p<0.005 
‡p<0.001. 
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Inhibition of calpain activity suppresses TGFβ1-induced Fibroblast-to-
Myofibroblast Transition (FMT) 
 Resident fibroblasts under pro-fibrotic conditions have the capacity to 
transform into myofibroblasts and promote organ fibrosis (Kendall and Feghali-
Bostwick 2014). Recent data from a kidney fibrosis model suggests that almost 
half of the myofibroblast population derives from proliferating resident fibroblasts 
(LeBleu, Taduri et al. 2013). Due to this potential additional source of 
myofibroblasts in promoting fibrosis, we tested the role of calpains during 
Fibroblast-to-Myofibroblast transition (FMT). Primary Normal Human Lung 
Fibroblasts (NHLF) were treated with TGFβ1 alone (Pegorier, Campbell et al. 
2010), or in combination with the calpain inhibitor MDL-28170 for 24 hours. 
Treatment with TGFβ1 caused an increase in αSMA expression, which was 
inhibited in the presence of the calpain inhibitor MDL-28170 in a dose-dependent 
manner (Figure 8). These data suggest that calpain inhibition may be an 
applicable strategy for multiple cell types susceptible to mesenchymal transition, 
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Figure 8: Western blot-assessment of a marker of TGFβ1-induced FMT in the 
presence of pharmacological calpain inhibitor MDL-28170. A) NHLF (lung 
fibroblast) cells were treated with TGFβ1 (5ng/mL) for 48 hours in the presence 
or absence of pretreatment with MDL-28170 (started 24 hours prior to stimulation 
with TGFβ1). B) Results are normalized to GAPDH expression and indexed to 
the TGFβ1 alone signal (set to 1.0). Results reflect experiments performed in 
biological triplicate. Statistics were calculated using Student’s t-test: *p<0.05 






Suppression of calpain activity induces Mesenchymal-to-Epithelial Transition 
 Mesenchymal-to-Epithelial transition (MET) is a process in which a cell 
loses myofibroblast characteristics and adopts an epithelial phenotype. MET is 
involved in early development, best characterized in kidney organogenesis 
(Kreidberg, Sariola et al. 1993). MET has also been implicated in the ability of 
metastasizing cells to establish tumors at distant sites (Yang and Weinberg 
2008) and potentially complicates the use of EMT-inhibitors in cancer therapy. In 
the context of fibrosis, MET could provide a highly desirable therapeutic benefit 
for patients in later stages of disease. We thus assessed the effect of inhibiting 
calpain activity in cells that had already undergone EMT. NMuMG cells were 
treated with TGFβ1 for 72 hours to induce EMT. Cells were then treated with 
MDL-28170, in addition to TGFβ1, for 48 and 72 hours (Figure 9). Cells treated 
with TGFβ1 and MDL-28170 showed a dose-dependent regression in αSMA 
expression over time, when compared to cells that received only TGFβ1.  
 The MET process requires not only loss of mesenchymal markers, but 
also reacquisition of an epithelial cell expression repertoire. We therefore 
characterized the effect of calpain inhibition on E-cadherin expression in cells 
that had undergone EMT. NMuMG Cells were grown to confluence on glass 
coverslips, serum starved (0.5% serum) for 24 hours, and treated with TGFβ1 for 
72 hours to establish EMT (Figure 10A). We then sought to assess the effect of 
removing TGFβ from the media, or maintaining TGFβ1 with the addition of MDL-
28170 or the TGFβ receptor kinase inhibitor SB431542. Cells were harvested 
after 48 or 72 hours and analyzed by immunofluorescence. Reacquisition of E-
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cadherin expression was observed at both time points in cells that had TGFβ1 
removed or were treated with a TGFβ receptor kinase inhibitor (Figure 10B,C), as 
previously reported (Gal, Sjoblom et al. 2008).  We were able to demonstrate for 
the first time that the same effect is achieved upon calpain inhibition despite 
ongoing exposure of the cells to TGFβ1 (Figure 10B,C). These data suggest that 
calpain activity is required to both induce and maintain a mesenchymal state in 
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Figure 9: Pharmacological calpain inhibitor MDL-28170 induces Mesenchymal-
to-Eplithelial transition.  A) Representative western blot of NMuMG cells pre-
treated for 48 hours with TGFβ1 followed by treatment with TGFβ1±MDL-28170 
for 48 or 72 hours. Membranes probed for αSMA and GAPDH as a loading 
control. B) Results are normalized to GAPDH expression and indexed to the 72 
hour post-EMT TGFβ1alone signal (set to 1.0) Results reflect experiments 
performed in biological triplicate. Statistics were calculated using Student’s t-test: 





   
Figure 10: Treatment with pharmacological calpain inhibitor MDL-28170 induces 
morphological changes associated with MET. A) NMuMG cells were treated with 
TGFβ1 (5ng/mL) for 72 hours to establish EMT and verified by loss of E-cadherin 
and formation of stress fibers. These cells were then maintained in media with 
TGFβ1, media that was not supplemented with TGFβ1, media containing TGFβ1 
and MDL-28170, or media with TGFβ1 and TGFβ receptor kinase inhibitor 
SB431542 for B) 48 hours C) 72 hours. Cells were stained for the epithelial 
marker E-cadherin, and F-actin. Scale bar: 100μm. 
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Chapter 3 
Calpastatin-Mediated Inhibition of Epithelial- and Endothelial-to-Mesenchymal 




 Calpain activity is physiologically regulated by the expression of 
calpastatin, an endogenous calpain inhibitor that prevents catastrophic 
unregulated proteolysis inside the cell (Goll, Thompson et al. 2003). Calpastatin 
is the most specific calpain inhibitor known with an IC50 in the low nanomolar 
range (Hanna, Campbell et al. 2008), likely the result of co-evolution with the 
enzyme (Betts, Weinsheimer et al. 2003, Tompa 2010). 
Global calpain activity within the cell is determined by the relative levels of 
calpastatin expression and calpain proteolytic activity. Under typical physiological 
conditions, calpastatin reversibly binds and suppresses calpain activity (Goll, 
Thompson et al. 2003). Sufficiently high calpain activity can overcome this 
suppression by cleaving calpastatin, suggesting a mutually antagonistic 
relationship.  
Calpastatin exclusively inhibits dimeric calpains because it requires 
binding to both the large catalytic subunit (CAPN1, CAPN2, CAPN9) and the 
small regulatory subunit (CAPNS1, CAPNS2) (Hanna, Campbell et al. 2008). 
Delineation of the structure of the calpain-calpastatin complex revealed that 
calpastatin binds to regions flanking the calpain substrate-recognition cleft, but 
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loops out of the protease active site to escape cleavage (Hanna 2008). 
Calpastatin has high affinity for activated calpains due its recognition of 
supplementary binding sites that are present only in the Ca2+ bound conformation 
(Hanna, Campbell et al. 2008). Each calpastatin molecule contains four 
calpastatin inhibitory domains; while all domains are capable of inhibiting calpain, 
they have significantly different dissociation constants (Hanna, Campbell et al. 
2008). The functional unit for calpain inhibition can be reduced to a 27 amino 
acid peptide encoded within Exon 1B (Ishima, Tamura et al. 1991, Betts, 
Weinsheimer et al. 2003) 
  Calpastatin has been studied most frequently with regard to its effect on 
degradation of post-mortem muscle proteins and commercial animal meat quality 
(Nonneman, Lindholm-Perry et al. 2011, Chung and Davis 2012, Bagatoli, 
Gasparino et al. 2013, Huang, Huang et al. 2014, Ropka-Molik, Bereta et al. 
2014). With regard to EMT-associated metastasis, calpastatin expression was 
found to be significantly lower in tissue derived from invasive breast cancers 
compared to non-invasive breast tumors (Storr, Mohammed et al. 2011). In 
contrast, overexpression of calpastatin in melanoma cells of mice increased 
metastasis to lymph nodes and resistance to apoptosis, though the relevance of 
this artificial cancer model is likely limited (Raimbourg, Perez et al. 2013). 
 In experiments described in this chapter, we have over-expressed 
calpastatin in order to assess the effect of dimeric calpain activity inhibition on 





Cloning (NMuMG Epithelial Cells) 
 A cDNA clone expressing full-length mouse calpastatin was purchased 
from Invitrogen (MGC 3710078). The coding sequence for calpastatin was 
amplified by PCR with primers containing restriction sites for EcoRI (5’) and SalI 
(3’). Flanking restriction sites were digested with EcoRI and SalI to create sticky 
ends, and the cDNA amplimer was gel purified. The bicistronic vector pCMV-
IRES-AcGFP from Clontech (632435) was digested with EcoRI and SalI, 
followed by treatment with antarctic phosphatase (NEB M0289) and the vector 
was gel purified. Vector and insert were ligated with a 1:3 ratio using T4 DNA 
ligase (M0202). Ligated DNA was used to transform OneShot TOP10 chemically 
competent cells from Invitrogen (C4040-10). Bacteria were plated on LB-
ampicillin plates and positive clones screened by DNA digest and DNA 
sequencing. 
 
Transfection (NMuMG Epithelial Cells) 
NMuMG cells were transfected with pCMV-Cast-AcGFP or pCMV-IRES 
using Lipofectamine 2000 according to the manufacturer’s instructions. Cells 
were transfected for 5 days, split, and selected for stably integrated clones using 
Geneticin (400ug/mL). A polyclonal cell line was established and confirmed to 
express AcGFP by live cell fluorescent microscopy.  
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Western Blot (NMuMG Epithelial Cells) 
Western blot analysis was carried out using the same procedures outlined 
in Chapter 2 of this thesis unless otherwise indicated. Additionally, membranes 
were probed for AcGFP using Living Colors Av Monoclonal Antibody JL-8 from 
Clontech (632380) at a 1:1000 dilution.  
 
Cell Culture (Endothelial Cells) 
Primary Porcine Aortic Endothelial Cells (PAVEC) were harvested using 
the previously described methods (Gould and Butcher 2010). PAVECs were 
grown in flasks coated with 50 μg/mL rat tail collagen I from BD Biosciences 
(354249). Cells were cultured at 370C and 5% CO2 in DMEM supplemented with 
10% FBS, 1% penicillin-streptomycin, and 50 U/mL heparin. Culture medium was 
changed every 48 hours and cells were passaged with 0.05% Trypsin-EDTA 1:3 
at confluence.  The purity of endothelial population was monitored via 
quantitative real-time PCR, western blot, and immunofluorescent assessment. 
Only cultures with consistent PECAM1 and CDH5 (encoding VE-cadherin) 
expression, cobblestone morphology, and non-detectable αSMA expression were 
used. αSMA levels were measured via Quantitative PCR (> 37 cycle threshold), 
western blot, and immunofluorescence. PAVEC were used between passage 





Transfection (Endothelial Cells) 
PAVECs were electroporated in solution with plasmids encoding for either 
mouse calpastatin (pEF1α-Cast-IRES-IRFP) or empty vector (pEF1α-IRES-
AcGFP) using the Neon transfection system (Invitrogen, Carlsbad, CA) as 
previously described (Mahler, 2013). Cells were then seeded and cultured for up 
to 48 hours before addition of TGFβ1 (10ng/mL) to induce EnMT. Cells were 
harvested at 48 hours after addition of TGFβ1. 
 
RNA Extraction/Quantitative PCR (Endothelial Cells) 
RNA extractions were performed using a Qiagen RNeasy Kit (74106) and 
RNA was reverse transcribed to cDNA using the Invitrogen SuperScript III RT-
PCR kit with oligo(dT) primer (1808051-051). Sufficient quality RNA was 
determined by an absorbance ratio A260/A280 of 1.8-2.1, while the quantity of 
RNA was determined by measuring the absorbance at 260nm (A260). 
Quantitative PCR experiments were conducted using the Bio-Rad CFX96 cycler, 
with 40 cycles per sample. TaqMan® probes were used to detect expression of, 
ACTA2 (encoding αSMA; Ss04245588_m1), CDH1 (encoding E-cadherin, 
Ss03377287_u1), VIM (encoding Vimentin; Ss04330801_gH), MMP2 (encoding 
MMP-2; Ss03394318_m1), MMP9 (encoding MMP-9; Ss03392092_g1) and 
GAPDH (encoding GAPDH; Ss03375629_u1) as a loading control. Ct values 
were corrected for loading and calculated using the 2^-ΔCt method. The average 
numerical value of the TGFβ1 only treated sample was normalized to 1 for each 
gene. 
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Results and Discussion: 
 
Overexpression of Calpastatin Suppresses TGFβ1-induced EMT 
Overexpression of calpastatin remains one of the most specific methods 
to inhibit calpain activity. We designed a bicistronic vector containing cDNA for 
mouse calpastatin, followed by an internal ribosome entry site, and cDNA 
encoding Ac-green fluorescent protein. We chose this method to monitor 
calpastatin expression based on previous reports that calpastatin protein 
migrates unpredictably on SDS-PAGE gels (Takano, Maki et al. 1988), potentially 
confounding interpretation of western blots. The prevailing hypothesis is that 
calpastatin adopts an unstructured conformation in its unbound state, retarding 
movement in a gel. Calpastatin and empty vector control constructs were 
transfected into NMuMG cells and stable polyclonal cell lines were established. 
 Overexpression of calpastatin completely abrogated TGFβ1-induced 
αSMA expression in NMuMG cells when compared to controls (Figure 11). As 
expected, calpastatin expression also prevented TGFβ1-induced filamin A 
cleavage but did not influence proximal events in the canonical TGFβ signaling 
cascade (i.e. phosphorylation of SMAD2). TGFβ1-treated cells overexpressing 
calpastatin maintained expression of the epithelial marker E-cadherin and a 
cortical distribution of F-actin compared to TGFβ1 treated NMuMG cells 
transfected with an empty vector (Figure 12). The superior inhibition of TGFβ1-
induced αSMA expression by calpastatin, when compared to the 
pharmacological inhibitors MDL28170 or calpeptin may relate to its greater 
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potency and specificity for calpain inhibition. However, it seems notable that 
calpastatin and pharmacologic inhibitors of calpains achieved comparable 
suppression of filamin A cleavage. The disparity between suppression of TGFβ1 
induced αSMA and filamin A cleavage could be attributed to different relative 
contributions of various calpain isoforms to each event. As previously stated, 
calpastatin is known to inhibit CAPN1, CAPN2, and CAPN9. Among these 
calpain isoforms, CAPN9 is unique in its restricted expression pattern and in the 
amino acid sequence that characterizes its substrate binding cleft (compared to 
CAPN1 and CAPN2) (Davis, Walker et al. 2007). It follows that a competitive 
inhibitor, such as calpastatin, may have differential binding affinities for CAPN9 
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Figure 11: Western blot-assessment of markers of TGFβ1-induced EMT and 
calpain activity with overexpression of calpastatin. A) Stable cell lines derived 
from NMuMG cells transfected with calpastatin or an empty vector were treated 
with TGFβ1 (5ng/mL). B) Results are normalized to GAPDH expression and 
indexed to the 72 hour TGFβ1 alone signal (set to 1.0). Results reflect 
experiments performed in biological triplicate. Statistics were calculated using 








Figure 12: Overexpression of calpastatin inhibits TGFβ1-induced morphological 
changes associated with TGFβ1-induced EMT. Immunofluorescence NMuMG 
cells expressing calpastatin or empty vector after 48 hours of treatment with 
TGFβ1 (5ng/mL). Cells stained for epithelial marker E-cadherin (green), F-actin 

















Overexpression of Calpastatin Suppresses TGFβ1-induced EnMT 
Endothelial-to-Mesenchymal Transition (EnMT) has been shown to play a 
pivotal role in pulmonary arterial hypertension (Arciniegas, Frid et al. 2007, 
Ranchoux, Antigny et al. 2015), chronic kidney disease associated-renal fibrosis 
(He, Xu et al. 2013), and cardiac fibrosis (Goumans, van Zonneveld et al. 2008, 
Yoshimatsu and Watabe 2011, Xu, Friehs et al. 2015). A previous study showed 
that suppression of calpain activity in bovine aortic endothelial cells abolished 
their ability to form stress fibers when plated on fibronectin (Kulkarni, Saido et al. 
1999). Primary Porcine Aortic Valve Endothelial Cells (PAVEC) transfected with 
a control vector and treated with TGFβ1 for 48 hours expressed high levels of 
mRNA for ACTA2 (encoding αSMA) and VIM (encoding vimentin), as measured 
by quantitative PCR (Figure 13). These cells also expressed high levels of mRNA 
for MMP2/9 (encoding MMP-2 and MMP9, respectively) and low levels for CDH1 
(encoding E-cadherin), both indicators of EnMT. Transfection with a mouse 
calpastatin-expressing vector blocked TGFβ1-induced ACTA2 expression and 
CDH1 downregulation, but only partially suppressed VIM and MMP2/9 mRNA 
expression. A prior study found that calpastatin-overexpressing transgenic mice 
exhibited decreased cardiovascular fibrosis after chronic angiotensin II infusion 
(Letavernier, Perez et al. 2008). Based on our data, this finding could have been 
due to suppression of EnMT. These data further support the hypothesis that 
proteolytic activity of a calpain heterodimer is required in multiple contexts for 
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Figure 13: Quantitative PCR analysis of TGFβ1-induced expression of EnMT-
genes in PAVEC (endothelial) cells overexpressing calpastatin. Cells were 
transiently transfected with a Cast expressing vector or empty vector for 48 
hours, and then treated with TGFβ1 (10ng/mL) for an additional 48 hours. 
Messenger RNA expression levels were corrected for loading to Gapdh and 
normalized to the average value of samples transfected with control siRNA and 
treated with TGFβ1. Results reflect experiments performed in biological 







The CAPN9/CAPNS2 Heterodimer is Critical for TGFβ1 Induced Epithelial- and 




 The data presented in the previous chapters strongly supported the 
hypothesis that the activity of a calpain heterodimers, which is inhibited by 
calpastatin, is a critical requirement for TGFβ1-induced mesenchymal transition 
in both EMT and EnMT. However, the exact molecular identity of this 
heterodimer remained to be elucidated. In cell-free systems, CAPN1 and CAPN2 
are equally competent at cleaving most calpain substrates (Franco and 
Huttenlocher 2005). This suggests that isoform-specific functions at the cellular 
level are at least partly due to spatio-temporal regulation. Experimental strategies 
based on RNA interference (RNAi) have attempted to correlate individual calpain 
isoforms with specific cellular functions, but have often done so only within the 
context of a single cell-type. This can be problematic, especially in the case of 
highly similar calpains, such as CAPN1 and CAPN2, whose relative ratios differ 
between cell types in the same species or between same cell types in different 
species (Goll, Thompson et al. 2003).  
A phylogenetic analysis of the calpain superfamily concluded that the 
CAPN9 gene was present in a common vertebrate ancestor before the CAPN1 
and CAPN2 genes diverged (Macqueen and Wilcox 2014). These data suggest 
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that CAPN9 and CAPN1/CAPN2 could have evolved in vertebrates to fulfill 
different functions. Structural analysis of the large catalytic subunits found that 
the amino acid residues lining the substrate recognition site in CAPN1 and 
CAPN2 were very similar to each other, but significantly different from analogous 
residues in CAPN9 (Davis, Walker et al. 2007). This structural difference could 
be the basis for differential substrate cleavage (Davis, Walker et al. 2007) and a 
unique function.  
Current data regarding the recently discovered CAPNS2 is limited. Human 
CAPNS1 and CAPNS2 show 63% amino acid identity with and an additional 16% 
of residues that are strongly similar (Schad, Farkas et al. 2002). CAPNS2 shares 
several functions with CAPNS1, such as the ability to heterodimerize with 
CAPN2 (Schad, Farkas et al. 2002), and it can be inferred the same is true for 
the other large subunits CAPN1 and CAPN9, although this has not yet been 
directly proven. In contrast, Capns2 cannot compensate for the loss of Capns1, 
as evidenced by embryonic lethality of Capns1-/- mice (Arthur, Elce et al. 2000). 
In Chapter 4, we have used an RNAi strategy to knockdown expression of 










Transfection (NMuMG Epithelial Cells) 
 NMuMG cells were transfected with a SMARTpool mixture of 4 small 
interfering RNA (siRNA) purchased from GE Healthcare for each gene, targeting 
Capn1 (M-062006-01-0010), Capn2 (M-043027-01-0010), Capns1 (M-048840-
01-0010), Capns2 (M-014858-00-0010) or non-targeting missense control (D-
001206-13-50). Two siRNAs targeting Capn9 were custom synthesized by GE 
Healthcare using previously validated sequences (Chen 2010). Cells were 
transfected using GE Healthcare Dhrmafect 4 (T-2004-03) according to the 
manufacturer’s instructions. In brief, siRNA was diluted in Invitrogen OptiMEM I 
Reduced Serum Medium (11058021), as was Dharmafect 4. Diluted siRNA was 
mixed with diluted siRNA and incubated at room temperature for 20 minutes. 
NMuMG cells in DMEM containing 0.5% Serum and 10μg/mL insulin were 
treated with the siRNA/tranfection complex at a final siRNA concentration of 
100nM. 
 
Induction of EMT (NMuMG Epithelial Cells) 
 NMuMG cells were treated with TGFβ1 (5ng/mL) 24 hours after 
transfection with siRNA. Cells were treated with TGFβ1 for 48 hours as described 





Western blot analysis was carried out using the same procedures outlined 
in Chapter 2 of this thesis with the following addendums. Membranes were 
probed with rabbit anti-CAPN1 from Cell Signaling Technologies (2556) at a 
1:1000 dilution, rabbit anti-CAPN2 from Cell Signaling Technologies (2539) at a 
1:1000 dilution, mouse anti-CAPN9 from Abnova (H00010753-M02) at a 1:1000 
dilution, rabbit anti-CAPNS2 from Lifespan Biosciences (LS-C133503) at a 
1:1000 dilution, in diluted blocking buffer overnight at constant rocking in 4C.  
 
Cell Culture (Endothelial Cells) 
Primary Porcine Aortic Endothelial Cells (PAVEC) were harvested and 
cultured as described in Chapter 2 of this thesis.  
 
Transfection (Endothelial Cells) 
PAVECs were electroporated in solution with siRNA targeting CAPNS2 
from GE Healthcare (M-014858-00-0010) or non-targeting missense control from 
GE Healthcare (D-001206-13-50) using the Invitrogen Neon transfection system 
as previously described (Mahler, Farrar et al. 2013). Cells were then seeded and 
cultured for up to 48 hours before addition of TGFβ1 (10ng/mL) to induce EnMT. 
 
RNA Extraction/Quantitative PCR (Endothelial Cells) 
RNA extractions and quantitative PCR were conducted as described in 
Chapter 3.  
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Immunofluorescence (Endothelial Cells) 
 Samples were fixed in 4% paraformaldehyde overnight at 4C. Samples 
were then washed for 15 minutes on a rocker 3 times with PBS, permeabilized 
with 0.2% Triton-X 100 for 10 minutes, and washed another 3 times with PBS. 
Samples were incubated overnight at 4C in a 1% BSA blocking solution followed 
by another 4C overnight incubation with either rabbit anti-human E-cadherin from 
Abcam (ab53033) at a 1:100 dilution, and mouse anti-human vimentin from 
Invitrogen (18-0052) at a 1:100.  After 3 washes for 15 minutes with PBS, 
samples were exposed to Alexa Fluor 488 or 568 conjugated, species-specific 
secondary antibodies at 1:100 in 1% BSA for 2 hours at room temperature. Three 
more washes with PBS for 15 minutes were followed by incubation with either 
DRAQ5 far red nuclear stain from Life Technologies (62251) at a 1:1000 dilution. 
 
RNA Extraction/Quantitative PCR (Mouse Organs) 
A C57Bl6 wild-type mouse was euthanized, perfused with PBS, and 
harvested for various organs. RNA extractions and quantitative PCR were 
conducted as described in Chapter 3. Quantitative PCR was performed using 
TaqMan® probes from Applied Biosystems for mouse Capn1 
(Mm00482964_m1), Capn2 (Mm00486669_m1), Capn9 (Mm00499260_m1), 
Capns1 (Mm00501568_m1), Capns2 (Mm03991531_s1), and Gapdh 






Knockdown of CAPN1 does not inhibit TGFβ1-induced EMT 
 CAPN1 expression was assessed by western blot and, as expected, it 
was found to be expressed in NMuMG cells under steady-state conditions; its 
levels did not change upon treatment with TGFβ1 (Figure 14). Knockdown of 
CAPN1 by siRNA had no effect on TGFβ1-induced expression of αSMA, 
suggesting that this isoform is not the critical driver of EMT. Loss of Capn1 is 
seldom associated with severe phenotypic consequences, which may be due to 
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Figure 14: Western blot-assessment of a marker of TGFβ1-induced EMT after 
RNAi-mediated knockdown of Capn1. A) NMuMG (epithelial) cells were 
transfected with siRNA targeting Capn1 or control siRNA 24 hours before 
treatment with TGFβ1 (5ng/mL). Cells were harvested 48 hours after treatment 
with TGFβ1 B) Protein levels were corrected for loading by GAPDH and 
normalized to the levels of present in samples transfected with a control siRNA 
and treated with TGFβ1. Results reflect experiments performed in biological 











Knockdown of CAPN2 does not inhibit TGFβ1-induced EMT 
CAPN2 has been shown to cleave several cytoskeleton-associated 
proteins (talin, spectrin, paxillin, cortactin, and focal adhesion kinase) (Franco, 
Perrin et al. 2004). Inhibition of CAPN2-mediated cortactin processing results in 
unregulated actin polymerization and protrusions in the plasma membrane 
(Perrin, Amann et al. 2006). 
CAPN2 was expressed in NMuMG cells under steady-state conditions, but 
treatment with TGFβ1 increased its expression as assessed by western blot 
(Figure 15). Phorbol esters have also been shown to induce CAPN2 expression 
in HeLa cells, but did not alter expression of CAPN1 or CAPNS1 (Hata, Ohno et 
al. 1992). Despite its induction, knockdown of CAPN2 expression did not affect 
TGFβ1-induced αSMA expression. 
These data suggested that cleavage of structural proteins by CAPN2 is 
not required for EMT, and that perhaps cleavage of additional targets by other 
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Figure 15: Western blot-assessment of a marker of TGFβ1-induced EMT after 
RNAi-mediated knockdown Capn2. NMuMG (epithelial) cells were transfected 
with siRNA targeting Capn2 or control siRNA 24 hours before treatment with 
TGFβ1 (5ng/mL). Cells were harvested 48 hours after treatment with TGFβ1 B) 
Protein levels were corrected for loading by GAPDH and normalized to the levels 
of present in samples transfected with a control siRNA and treated with TGFβ1. 
Results reflect experiments performed in biological triplicate. Statistics were 






Knockdown of CAPNS1 does not inhibit TGFβ1-induced EMT 
Knockdown of CAPNS1 is a commonly used strategy to inhibit both 
CAPN1 and CAPN2. A rationale for adopting such an approach is to inhibit 
redundant activity between the two isoforms and achieve sufficient inhibition to 
affect function. CAPNS1 was expressed in NMuMG cells under steady-state 
conditions and was increased by treatment with TGFβ1. Despite this, knockdown 
of CAPNS1 by siRNA failed to inhibit TGFβ1-induced αSMA expression (Figure 
16). These results corroborate the previous findings showing that knockdown of 
CAPN1 or CAPN2 had no effect on TGFβ1-induced EMT. This also excludes the 
possibility that the combination of CAPN1 and CAPN2 is required for TGFβ1-
induced EMT. Until recently, CAPNS1 has been the only known small regulatory 
subunit component of a calpain heterodimer, making it necessary for all dimeric 
calpain function. The recent discovery of CAPNS2, however, has changed this 
paradigm. Dimeric calpain activity, found to be essential for TGFβ1-induced EMT 
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Figure 16: Western blot-assessment of a marker of TGFβ1-induced EMT after 
RNAi-mediated knockdown of Capns1. NMuMG (epithelial) cells were 
transfected with siRNA targeting Capns1 or control siRNA 24 hours before 
treatment with TGFβ1 (5ng/mL). Cells were harvested 48 hours after treatment 
with TGFβ1. B) Protein levels were corrected for loading by GAPDH and 
normalized to the levels of present in samples transfected with a control siRNA 
and treated with TGFβ1. Results reflect experiments performed in biological 











Knockdown of CAPN9 inhibits TGFβ1-induced EMT 
 Recent experimental evidence has shown that CAPN9 can heterodimerize 
with CAPNS1 to form a functional enzyme (Ravulapalli, Campbell et al. 2009) 
and therefore could be a critical isoform mediating TGFβ1-induced EMT. 
However, under steady-state conditions, CAPN9 expression is limited to the 
gastrointestinal tract (Hata, Abe et al. 2010). Western blot analysis showed that 
while CAPN9 is not expressed in NMuMG cells under steady state conditions, its 
expression is greatly increased by treatment with TGFβ1 (Figure 17). Importantly, 
partial knockdown of CAPN9 was able to potently suppress TGFβ1-induced 
expression of αSMA and faithfully recapitulated the effects of calpain inhibitors on 
EMT.  
These data begin to suggest that induction of tissue-specific calpain 
isoforms, rather than increased function of the ubiquitously expressed ones, 
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Figure 17: Western blot-assessment of a marker of TGFβ1-induced EMT after 
RNAi-mediated knockdown of Capn9. NMuMG (epithelial) cells were transfected 
with siRNA targeting Capn9 or control siRNA 24 hours before treatment with 
TGFβ1 (5ng/mL). Cells were harvested 48 hours after treatment with TGFβ1. B) 
Protein levels were corrected for loading by GAPDH and normalized to the levels 
of present in samples transfected with control siRNA and treated with TGFβ1. 
Results reflect experiments performed in biological triplicate. Statistics were 







Knockdown of CAPNS2 inhibits TGFβ1-induced EMT 
Like CAPN9, CAPNS2 was not expressed in NMuMG cells under steady 
state conditions (Figure 18). In contrast, treatment with TGFβ1 was able to 
induce expression of CAPNS2 and the mesenchymal marker αSMA. Knockdown 
of CAPNS2 in TGFβ1 treated cells was able to completely block expression of 
αSMA. We hypothesize that the stronger effect of CAPNS2, compared to 
CAPN9, may be due to variable efficiency of RNAi suppression and/or dosage 
dependence with regard to EMT. Alternatively, CAPNS2’s may have the ability to 
form heterodimers with other calpain isoforms. Although CAPN1, CAPN2, and 
CAPN9 have been the only isoforms described to heterodimerize with CAPNS1 
(Ravulapalli, Campbell et al. 2009), CAPNS2 may be able to form heterodimers 
with isoforms that are not CAPNS1 partners. These data may provide the first 
evidence for a unique function for CAPNS2, and warrant additional studies on its 
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Figure 18: Western blot-assessment of a marker of TGFβ1-induced EMT after 
RNAi-mediated knockdown of Capns2. A) NMuMG (epithelial) cells were 
transfected with siRNA targeting Capns2 or control siRNA 24 hours before 
treatment with TGFβ1 (5ng/mL). Cells were harvested 48 hours after treatment 
with TGFβ1. B) Protein levels were corrected for loading by GAPDH and 
normalized to the levels of present in samples transfected with a control siRNA 
and treated with TGFβ1. Results reflect experiments performed in biological 

















Figure 19: Expression of dimeric calpain isoforms in various mouse organs as 
assessed by quantitative PCR. A) Large catalytic calpain subunit B) Small 







Knockdown of CAPNS2 inhibits TGFβ1-induced EnMT 
 To further characterize the role of CAPNS2 during mesenchymal 
transition, we tested the effect of its inhibition on EnMT in Primary Porcine Aortic 
Valve Endothelial Cells (PAVEC). Quantitative PCR analysis revealed that 
treatment with TGFβ1 for 48 hours induced expression of mRNA encoding for 
several mesenchymal marker proteins consistent with induction of EnMT, such 
as ACTA2 (encoding αSMA) and VIM (encoding vimentin), MMP2 (encoding 
MMP-2), and MMP9 (encoding MMP9); and decreased expression of CDH1 
(encoding E-cadherin; Figure 20). Treatment with TGFβ1 induced expression of 
CAPNS2, and knockdown by siRNA targeting CAPNS2 resulted in suppression 
of mesenchymal marker proteins and maintenance of CDH1 expression. While 
overexpression of calpastatin in PAVECs during EnMT only partially suppressed 
expression of MMP2/9 and VIM (Figure 13), knockdown of CAPNS2 was able to 
completely block TGFβ1-induced MMP2/9 expression and more strongly inhibit 
expression of VIM (Figure 20) 
Immunofluorescence of PAVECs undergoing TGFβ1-induced EnMT 
illustrates that knockdown of CAPNS2 by siRNA was able to block 
downregulation of E-cadherin and suppress expression of vimentin (Figure 21). 
Morphologically, TGFβ1-induced EnMT caused the PAVECs to disassociate and 
adopt a spindle shape appearance, which was suppressed by inhibition of 
CAPNS2 expression (Figure 21). These data indicate that in endothelial cells, 
expression of the CAPNS2 is induced by high TGFβ1 signaling and that the 
presence of CAPNS2 is critical EnMT. We hypothesize that CAPNS2 forms a 
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complex with CAPN9, and as a heterodimer, has activity that is required for 
TGFβ-induced EMT. The robust ability of calpain inhibitors to suppress TGFβ-
induced mesenchymal transition in multiple cell types, limited expression of the 
critical calpain isoforms, and viability of the CAPN9-/- mice all strongly support 
targeting CAPN9 or CAPNS2 dependent activity for the treatment of TGFβ-
mediated mesenchymal transition and associated pathologies, such as fibrosis. 
In later chapters, we will explore the effect of inhibiting CAPNS2 and/or CAPN9 
on TGFβ1-induced mesenchymal transition in additional cell types and EMT-
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Figure 20: Quantitative PCR analysis of TGFβ1-induced expression of EnMT-
genes in PAVEC (endothelial) cells after suppression of CAPNS2 expression. 
Cells were transiently transfected with a siRNA targeting CAPNS2 or control 
siRNA for 48 hours, and then treated with TGFβ1 (10ng/mL) for an additional 48 
hours. Messenger RNA expression levels were corrected for loading to GAPDH 
and normalized to the average value of samples transfected with control siRNA 
and treated with TGFβ1. Results reflect experiments performed in biological 











Figure 21: Knockdown of Capns2 inhibits morphological changes during TGFβ1-
induced EnMT. PAVEC (endothelial) cells were transfected with a siRNA 
targeting CAPNS2 or a control siRNA for 48h, followed by treated with TGFβ1 
(10ng/mL) for 48 hours. Cells were stained for E-cadherin (green), Vimentin 










Calcineurin as a Critcal Calpain Substrate for EMT 
 
Introduction: 
 The experiments presented in the previous chapters supports a model by 
which TGFβ signaling-dependent expression and activation of a 
CAPN9/CAPNS2 heterodimer is required for TGFβ-induced mesenchymal 
transition in a variety of in vitro models. Once activated, the CAPN9/CAPNS2 
heterodimer can cleave and thus modify the activity of critical substrates, to 
activate a specific transcriptional program to mediate transition to a 
mesenchymal state. To identify possible critical mediators, we initially cross-
referenced known calpain substrates with proteins involved in mesenchymal 
transition. During this literature search, one study provided evidence for a 
possible downstream mechanism consistent with our hypothesis. 
A study by Molkentin and colleagues employed a genome-wide screen to 
identify mediators of fibroblast-to-myofibroblast transition (FMT) in cardiac 
fibroblasts (Davis, Burr et al. 2012). In this study, expression of either interleukin-
6 (IL-6) or the calcium channel TRPC6, in cultured cardiac fibroblasts, was 
sufficient to induce expression of αSMA and FMT. Additionally, primary dermal 
fibroblasts derived from Trpc6-/- mice were resistant to TGFβ1-induced αSMA 
expression and FMT (Davis, Burr et al. 2012). In vivo, Trpc6-/- mice subjected to 
a dermal punch biopsy exhibited impaired wound healing/closure compared to 
wild-type littermates and significantly fewer αSMA positive myofibroblasts on the 
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boarder of the wound (Davis 2012), both of which are consistent with 
suppression of FMT (Yan 2010).  
Moreover, these authors also showed that TGFβ1 treatment induced 
expression of Trpc6 (but not other TRPC family members) in cultured cardiac 
fibroblasts and this was mediated through a p38 MAPK-dependent mechanism, 
independent of SMAD signaling (Davis, Burr et al. 2012). Chronic exposure to 
TGFβ1 (48 hours) or overexpression of TRPC6 in cardiac fibroblasts, resulted in 
increased cytosolic calcium concentration, but acute treatment with TGFβ1 did 
not, suggesting a gene expression-dependent mechanism (Davis, Burr et al. 
2012). 
Our data in NMuMG epithelial cells also found a significant increase in 
calpain activity 48 hours after TGFβ treatment, but not at 24 hours (Figure 1) and 
similarly suggests that transcriptional changes are required. However, some 
studies have specifically implicated the TRPM7 divalent cation channel, rather 
than TRPC6, in mesenchymal transition (Figure 7). Increased expression of 
TRPM7 is associated with in increased calpain activity (Su, Agapito et al. 2006), 
and cardiac fibrosis (Du, Xie et al. 2010). It is possible that TRPM7 and TRPC6 
might facilitate calcium influx by working in a hetero-oligomeric complex, as has 
been shown to occur for other members of this class of channels (Alessandri-
Haber, Dina et al. 2009, Ma, Qiu et al. 2010, Davis, Burr et al. 2012).  
TRPC6-mediated Ca2+ influx has been shown to activate the calcineurin-
Nuclear Factor of Activated T-cells (NFAT) pathway (Kuwahara, Wang et al. 
2006). Calcineurin is a heterodimeric protein phosphatase, composed of a 
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catalytic A-chain (CnA) and a regulatory B-chain (CnB), both of which are 
required for activation of NFAT transcription factors.  
Calcineurin was first identified as the target of the widely used 
immunosuppressive agent cyclosporine and as a critical mediator for activation of 
immune T cells (Clipstone and Crabtree 1992, Schreiber and Crabtree 1992). In 
addition to its role in T cell activation, calcineurin has also been shown to play a 
role in many other cellular processes including signaling during development of 
the immune, nervous, cardiovascular, and musculoskeletal systems (Aramburu, 
Heitman et al. 2004). Inhibitors of calcineurin, such as cyclosporine, have been 
used as potent immunosuppressive agents to treat autoimmune disorders and 
prevent organ transplant rejection, but are also associated with severe side 
effects.  
In response to an increase in intracellular Ca2+ concentration, the 
regulatory CnB subunit of calcineurin binds Ca2+ and catalyzes a conformational 
change in the CnA subunit that exposes the calmodulin binding site (CaM) (Yang 
and Klee 2000).  Binding of Ca2+-bound calmodulin to the CaM site of CnA 
displaces the auto-inhibitory domain of CnA from the catalytic active site resulting 
in activation of calcineurin phosphatase activity (Rumi-Masante, Rusinga et al. 
2012, Ye, Feng et al. 2013). 
A major downstream target of calcineurin phosphatase activity is the 
NFAT family of transcription factors. Calcineurin-dependent dephosphorylation of 
NFAT uncovers the nuclear localization signal and allows its translocation to the 
nucleus (Clipstone and Crabtree 1992) where it can induce expression of a 
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variety of targets in concert with other transcription factors (Crabtree and Olson 
2002). There is significant redundancy in function between the four NFAT 
isoforms based on the relatively benign phenotypes of single isoform knockout 
mice, but more severe phenotypes of mice lacking multiple combinations of 
isoforms (Crabtree and Olson 2002). 
Expression of constitutively active calcineurin, lacking the C-terminal auto-
inhibitory domain, (Hubbard and Klee 1989, O'Keefe, Tamura et al. 1992) in 
cultured cardiac fibroblasts was sufficient to induce expression of αSMA and 
induce FMT, while overexpression of the endogenous calcineurin inhibitor cain 
(Lai, Burnett et al. 1998) was able to block TGFβ1-dependent and TRPC6-
overexpression-induced FMT (Davis, Burr et al. 2012). Inhibition of NFAT using 
the pharmacological inhibitor VIVIT was also able to block TGFβ1-dependent and 
TRPC6 overexpression-induced FMT (Davis, Burr et al. 2012). 
Interestingly, calpains are known to cleave within the auto-inhibitory 
domain of calcineurin, resulting in its activation (Wang, Roufogalis et al. 1989, 
Shioda, Moriguchi et al. 2006). Additionally, calpains have been reported to 
cleave and inactivate the endogenous calcineurin inhibitor cain (a.k.a. cabin1) in 
response to ionomycin-induced calcium influx (Kim, Jo et al. 2002). Treatment 
with a calpain inhibitor, was able to suppress ionomycin-induced cleavage of cain 
and prevent activation of calcineurin (Kim, Jo et al. 2002). Based on these 
findings which support a role for calcineurin-mediated signaling in mesenchymal 
transition, and a role for calpain activity in activation of calcineurin phosphatase 
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activity, we hypothesized that calcineurin might be a critical CAPN9/CAPNS2 




Western Blot Analysis 
Western blot analysis was carried out using the same procedures outlined 
in Chapter 2 of this thesis. Membranes were probed with antibodies for rabbit 
anti-Calcineurin from StressMarq (SPC-175D) at a 1:1000 dilution, and goat anti-




Calcineurin as a Potential Calpain Substrate During Mesenchymal Transition 
NMuMG cells under steady state conditions express both the full length 
and cleaved forms of calcineurin, as assessed by western blot (Figure 22). The 
signal for the cleaved form of calcineurin is significantly higher compared to the 
full-length form, suggesting that calcineurin is predominantly in its cleaved form 
under these conditions (or possibly, that the antibody has a greater affinity for the 
cleaved form). Treatment of these cells with TGFβ greatly increases the level of 
cleaved calcineurin, and this increase is abrogated by siRNA-mediated CAPN9 
knockdown, suggesting that CAPN9 activity is required for processing of 
calcineurin in response to TGFβ. Additional experiments, targeting the other 
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dimeric calpain isoform subunits will be required to further characterize 
calcineurin processing by this mechanism. 
 In Figure 23, we propose a calcineurin-mediated mechanism to explain 
the function of calpains during TGFβ-induced mesenchymal transition. In this 
pathway, high TGFβ signaling causes increased levels of intracellular calcium 
through an indirect mechanism, possibly involving TRP channels, as suggested 
by previous studies (Davis, Burr et al. 2012). Calcium signaling by itself can 
activate calcineurin phosphatase activity through the classical, and reversible, 
calmodulin-dependent mechanism. Our data shows that acute exposure to 
TGFβ1 can induce expression of CAPN9/CAPNS2 (Figure 17,18), and that 
CAPN9 is necessary for TGFβ1-induced cleavage of calcineurin (Figure 22). This 
results in generation of an active phosphatase that would retain its activity, 
despite a subsequent decrease in intracellular calcium concentration. This 
cleaved form of calcineurin would not be subject to regulatory mechanisms that 
govern active, full-length calcineurin. As previously mentioned, calpains have 
been shown to cleave the endogenous calcineurin inhibitor cain (Kim, Jo et al. 
2002), further potentiating its ability to activate the calcineurin pathway. 
Activation of calcineurin by either of these signaling mechanisms eventually 
leads to expression of NFAT-responsive genes, including cytokines such as IL-6 
(Nilsson, Sun et al. 2007). It is worth noting that the same genetic screen used to 
identify TRPC6 as an inducer of FMT, also identified IL-6 (Davis, Burr et al. 
2012). Interleukin-6 has also been recognized as one of the few signaling 
molecules that can robustly induce myofibroblast differentiation that is 
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independent from TGFβ signaling (Hinz 2007) and would be in line with our 
proposed mechanism by placing it downstream of TGFβ. IL-6-/- mice exhibit 
delayed wound healing/closure in response to a punch biopsy (Lin, Kondo et al. 
2003, Gallucci, Lee et al. 2006), suggesting an impairment of non-developmental 
EMT. In the next chapter, we will explore the effect of inhibiting calpain isoforms 
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Figure 22: Western blot-assessment characterizing the effect of CAPN9 
knockdown on calcineurin cleavage during TGFβ1-induced EMT. A) NMuMG 
(epithelial) cells were transfected with siRNA targeting Capn9 or a missense 
control, 24 hours prior to treatment with TGFβ1 (5ng/mL) for 48 hours . B) 
Results are normalized to the levels present in samples transfected with control 
siRNA and treated with TGFβ1. Results reflect experiments performed in 
biological triplicate. Statistics were calculated using Student’s t-test: *p<0.05 
**p<0.01 †p<0.005 ‡p<0.001. C) Calcineurin domain structure in relation to 




Figure 23: Proposed mechanism for calpain-dependent cleavage of calcineurin 
during TGFβ-induced mesenchymal transition. High TGFβ signaling induces 
expression of TRPC6/TRPM7 ion-channels, which results in an increase in 
cytosolic Ca2+ concentration. In the canonical pathway, calmodulin binds Ca2+ 
and activates calcineurin. We show that high TGFβ signaling also induce 
expression of the CAPN9/CAPNS2 heterodimer, which can cleave the 
endogenous calcineurin inhibitor cain (resulting in its inactivation), and also 
cleave calcineurin within its auto-inhibitory domain (resulting in its constitutive 
activation;∆Calcineurin). Activated calcineurin de-phosphorylates NFAT, allowing 







Inhibition of the CAPN9/CAPNS2 Heterodimer in in Vivo Models of Fibrosis 
 
Introduction: 
 Although no ideal animal model for human fibrotic diseases exists, several 
attempts have been made to model the development of fibrosis in mouse in order 
to test the efficacy of anti-fibrotic therapies. The most commonly used models are 
bleomycin-induced lung fibrosis (Lee, Reese et al. 2014), carbon tetrachloride-
induced liver fibrosis (Paquet and Kamphausen 1975), and unilateral ureteral 
obstruction-induced kidney fibrosis (Sharma, Mauer et al. 1993). 
Bleomycin-induced lung fibrosis has been one of the most widely adopted 
models (Moore and Hogaboam 2008, Degryse and Lawson 2011). Bleomycin is 
an antibiotic that is clinically used as an intravenous chemotheraputic agent. 
Pulmonary fibrosis and (to a lesser degree) skin fibrosis are the most common 
side effects associated with bleomycin administration in humans. Relatively low 
levels of bleomycin hydrolase, the enzyme that metabolizes bleomycin, in these 
tissues might explain their susceptibility to fibrosis in response to this drug (Lazo 
and Humphreys 1983, Takeda, Masuda et al. 1996). Likewise, mouse strains that 
express higher levels of bleomycin hydrolase in the lungs, such as the Balb/C 
strain, have been found to be resistant to bleomycin-induced lung fibrosis 
(Filderman and Lazo 1991). 
It is thought that bleomycin-mediated degradation of DNA and consequent 
cell death (Mirabelli, Ting et al. 1982, Tounekti, Kenani et al. 2001) leads to 
secretion of pro-inflammatory cytokines (Tumor Necrosis Factor α, IL-1β, IL-13, 
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gp160, and IL-6) (Cavarra, Carraro et al. 2004) and the generation of pro-fibrotic 
myofibroblasts (Alipio, Jones et al. 2011, Aoyagi-Ikeda, Maeno et al. 2011, Zhao, 
Qin et al. 2014, Chen, Ye et al. 2015). In this model, myofibroblasts have been 
shown to be derived from mesenchymal transition of multiple cell types, including 
epithelial cells (Tanjore, Xu et al. 2009), endothelial cells, (Hashimoto, Phan et al. 
2010)), and fibroblasts (Chen, Zhang et al. 2013).  
In order to assess the effect of inhibiting Capn9 or Capns2 expression in 
fibrosis development, we used various strategies to test the effect of isoform-
specific suppression of calpain activity in the development of bleomycin-induced 
lung fibrosis. 
Currently there are no reported pharmacological calpain inhibitors that are 
specific for a single isoform. Therefore, in order to achieve isoform specific 
inhibition of calpain activity, we used intratracheal instillation of siRNA to 
specifically target Capns2 mRNA expression (Bonifazi, D'Angelo et al. 2010, 
Zafra, Mazzeo et al. 2014) and a Capn9-/- mouse model (Hata, Abe et al. 2010) 




Administration of siRNA targeting Capns2 and intratracheal bleomycin in mice. 
 Eight-week-old C57Bl6 male mice were purchased from Jackson 
Laboratories (000664). Mice were maintained on an ad libitum diet and standard 
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12 hour light/dark cycle in accordance with protocols set forth by Johns Hopkins 
University Institutional Animal Care and Use Committee (Protocol MO12M124).  
A SMARTpool of Accell siRNAs targeting Capns2 (sequence M-014858-00-0010) 
or Accell siRNA non-targeting missense control (sequence D-001206-13-50) 
were purchased from GE Healthcare. Small interfering RNAs were resuspended 
in 1x GE Healthcare siRNA buffer (B-002000-UB-100) at a concentration of 2.5 
nanomoles/50 μL. Bleomycin sulfate was purchased from Sigma (B5507-15UN) 
and dissolved in PBS for a final concentration of 0.05U/50μL. 
Mice were anesthetized with 250 μL of Avertin solution (2,2,2 
tribromoethanol dissolved in tert-amyl alcohol),diluted to 2.5% in PBS. For drug 
delivery, mice were first placed on a 45° inclined plane and intubated with a 
PennCentury microsprayer aerosolizing syringe (MSA-250) (Bivas-Benita, Zwier 
et al. 2005) with the assistance of a laryngoscope. Animals were first treated with 
siRNA targeting Capns2 or a non-targeting missense control at a dose of 2.5 
nanomoles in 50 μL of siRNA buffer solution. The following day, lung fibrosis was 
initiated in mice by treatment with intratracheally delivered 0.05U bleomycin in 
50uL saline vehicle, for a final dose of 2U/kg as previously described (Lee, 
Reese et al. 2014).  Direct intratracheal delivery of bleomycin was chosen to 
parallel the intratracheal delivery of siRNA and to maximize delivery to the lungs. 
Mice were analyzed 14 days after initial bleomycin injection and after treatment 
with siRNA targeting Capns2 or a non-targeting missense control according to 
the schedule shown in Figure 24. The dosing regimen was designed based on 
current data describing siRNA delivery into the lungs of mice (Yueksekdag, 
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Drechsel et al. 2010) and our own experience with in vitro experiments. Mice 
were euthanized with an intraperitoneal injection of 200 μL 10% ketamine 
solution, and perfused with PBS. For western blot analysis, lungs were isolated 
and sonicated in RIPA buffer. Samples were spun at 20,000g for 15 minutes and 
supernatant isolated for western blot analysis as described in Chapter 2. 
Membranes were probed using goat anti-Collagen I from Southern Biotech 
(1310-01), goat anti-Collagen III from Southern Biotech (1330-01), and goat anti-
GAPDH from Santa Cruz Biotechnology (sc-20457). For quantitative PCR 
analysis, RNA from lungs was isolated and processed as described in Chapter 4. 
 
Systemically Delivered Bleomycin-Induced Fibrosis Model in Capn9-/- mice 
 Capn9-/- mice have been previously described (Hata, Abe et al. 2010). 
Cryopreserved sperm from Capn9+/- mice (RBRC04790) was obtained from the 
Experimental Animal Division of RIKEN and rederived in mice on a C57Bl6 
background by the Johns Hopkins University School of Medicine Transgenic 
Core Laboratory. DNA from mice was extracted using the Qiagen DNeasy blood 
and tissue kit (69506). Mice were genotyped by PCR using the Bio-Rad iProofTM 
High Fidelity PCR kit (172-5331) with GC buffer. PCR primers were synthesized 
by Integrated DNA Technologies and using sequences and thermal cycling 
conditions as previously described (Hata, Abe et al. 2010). 
 Eight-week-old C57Bl6 male mice from Jackson labs, or Capn9-/- mice 
were treated with systemic bleomycin by osmotic pump as previously described 
(Lee, Reese et al. 2014). In brief, animals were anesthetized with 4% isofluorane 
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by gas mask under a ventilated hood. Mice were shaved and a small lateral 
incision was made between the scapulae. Each mouse was implanted with an 
Alzet Micro-osmotic pump (Model 1007D) filled with vehicle saline or a bleomycin 
solution prepared to achieve a dose of 100U/kg over a period of 7 days (Lee, 
Reese et al. 2014). The wound was closed using tissue clips and mice were 
allowed to recover. Pumps were explanted 10 days later to prevent release of 
toxic salts from the pump (Lee, Reese et al. 2014) and the wound was resealed 
with tissue clips. Lung fibrosis, which under this method of delivery, is primary 
localized of the subplural regions (Lee, Reese et al. 2014), was allowed to 
develop for an additional 25 days following removal of the pump. At the end of 
the trial, mice were euthanized with an intraperitoneal injection of 200 μL 10% 
ketamine and perfused with PBS. Right lung lobes were tied off with a suture and 
the trachea was cannulated with a blunted syringe that inflated the left lobe with 
warm 0.7% agarose in PBS. The left lung was allowed to solidify and fixed in 
10% formalin overnight. Fixed lungs were then transferred to 70% ethanol 
solution and sent to AML Laboratories (Baltimore, MD) for paraffin embedding, 
10 μm sectioning, and Masson Trichrome staining. Lungs were imaged on a 
Nikon Elipse 80i scope using a 10x objective lens under bright field and captured 








RNAi-mediated knockdown of CAPNS2 suppresses intratracheal bleomycin-
induced pulmonary fibrosis in a murine model. 
 In order to assess the anti-fibrotic potential of CAPNS2 inhibition, we 
monitored the levels of lung fibrosis in mice in which pulmonary fibrosis was 
induced by intratracheal administration of bleomycin concomitantly with control 
siRNA or siRNA targeting Capns2 (Figure 25). Western blot analysis of lungs 
from bleomycin-treated mice that had received control siRNA showed high levels 
of collagen I and collagen III compared to saline controls, although variable levels 
of Collagen I expression were observed. This variability may reflect uneven 
distribution of bleomycin upon delivery, causing some lung lobes to have more 
fibrosis relative to others within the same mouse. 
Lungs from bleomycin-treated mice that had received siRNA targeting 
Capns2 showed significantly lower levels of collagen I and collagen III compared 
to lungs derived from mice treated with control siRNA. Indeed, they expressed 
levels of collagen I and collagen III similar to those found in the lungs of saline-
treated animals. CAPNS2 was not present in lungs from vehicle treated mice but 
was highly expressed in lungs from mice treated with control siRNA and 
bleomycin. In contrast, lungs from mice treated with siRNA targeting Capns2 and 
bleomycin showed significantly lower levels of CAPNS2 compared to mice 
treated with control siRNA and bleomycin, confirming successful knockdown of 
our target. 
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Assessment of Capn9 expression by qPCR shows that this calpain 
isoform is greatly induced in lungs from bleomycin-treated mice when compared 
to saline-treated controls (Figure 25C); this is consistent with our previous 
observations (Figure 17) that, in most tissues, Capn9 is not expressed under 
physiological conditions, but it is induced by fibrotic stimuli such as TGFβ. 
We hypothesized that the therapeutic effect of CAPNS2 knockdown could 
be attributed to a requirement for CAPNS2 for the formation of a functional 
proteolytic heterodimer between this subunit and CAPN9, whose activity is 
necessary for TGFβ-induced EMT (Figure 17). We thus set out to directly test the 


























Figure 24: Dosing schedule for RNAi-mediated knockdown of Capns2 during 
intratracheal bleomycin-induced lung fibrosis. Mice were pretreated with siRNA 
targeting Capns2 or a non-targeting missense control before delivery of 
bleomycin. In addition, small interfering RNAs (siRNA) were also delivered on 
















Figure 25: Knockdown of Capns2 suppresses bleomycin-induced fibrosis in mice. 
Eight-week-old C57Bl6 mice were pretreated with intratracheal siRNA targeting 
Capns2 or a control siRNA. The next day, mice received an intratracheal 
injection of bleomycin (2U/kg) in PBS solution. From this time, mice siRNA 
targeting Capns2 or control siRNA every 3 days for a total of 3 additional doses 
as described in Figure 24. A) Protein isolated from lungs was analyzed by 
western blot for levels of Collagen I, Collagen III with GAPDH as a loading 
control. B) Western blots were quantitated and statistics calculated using 
Kruskal-Wallis non-parametric one-way analysis of variance. C) Quantitative 
PCR analysis of Capn9 mRNA levels in lungs from bleomycin treated lungs 
compared to vehicle treated lungs. Messenger RNA levels were normalized to 
lungs derived from mice treated with vehicle. 
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Capn9-/- mice are protected from systemically delivered bleomycin-induced lung 
fibrosis . 
Systemic delivery of bleomycin (via subcutaneous osmotic pump) allows 
for more uniform drug delivery compared to direct intratracheal instillation and 
results in subplural fibrosis, which is similar to scleroderma-associated lung 
fibrosis (Lee, Reese et al. 2014). We used this method to induce lung fibrosis in 
control mice and in mice in which CAPN9 had been genetically ablated (Hata, 
Abe et al. 2010). 
Histological analysis by Masson Trichrome staining of lungs derived from 
control mice treated with systemic bleomycin reveals severe subplural fibrosis all 
along the perimeter of the lung (Figure 26). When these lungs were inflated with 
0.7% agarose solution, the edges of the lungs failed to expand, while the center 
of the lung had relatively higher compliance and quickly enlarged. 
In stark contrast, lungs from Capn9-/- mice treated with bleomycin showed little to 
no fibrosis by histology and were virtually indistinguishable from wild type mice 
treated with saline. There were also significantly fewer infiltrating cells in the 
lungs from bleomycin-treated Capn9-/- mice or saline-treated wild type mice, as 
compared to bleomycin-treated wild-type animals. These data support the notion 
that CAPN9 is a critical mediator of bleomycin-induced fibrosis, and that CAPN9 
might represent an exciting new target for anti-fibrotic drugs, especially 
considering that we saw no evidence of a compensatory mechanism in response 




Figure 26: Capn9-/- mice are resistant to systemically delivered bleomycin-
induced lung fibrosis. Eight-week-old C57Bl6 wild-type or Capn9-/- mice were 
implanted with subcutaneous osmotic pumps that delivered 100U/kg bleomycin 
in a saline solution over a period of 7 days, was explanted 3 days later, and 
allowed to develop fibrosis for an additional 25 days. Control C57Bl6 wild-type 
mice were implanted with pumps delivering saline. Lungs were formalin fixed, 
paraffin embedded, sectioned and stained for fibrosis using Masson Trichrome. 







Epithelial-to-Mesenchymal Transition (EMT) is a complex biological 
process that has evolved to fulfill critical functions that are essential for both 
embryonic development and for tissue repair in response to injury (i.e. wound 
healing). Development-associated EMT purposefully functions to regulate the 
generation of diverse cell types in order to facilitate tissue/organ formation and 
does not involve fibrosis, inflammation, or obligate adoption of an invasive 
phenotype (Kalluri and Weinberg 2009). EMT during gastrulation has been 
shown to be primarily regulated by WNT signaling (Liu, Wakamiya et al. 1999, 
Skromne and Stern 2001), which is mediated through the TGFβ superfamily 
proteins NODAL and Vg1 (Collignon, Varlet et al. 1996, Shah, Skromne et al. 
1997, Varlet, Collignon et al. 1997, Skromne and Stern 2002, Chea, Wright et al. 
2005). 
In contrast, the EMT process that is initiated in response to tissue injury is 
closely linked to inflammation and leads to the generation of invasive 
myofibroblasts; in the presence of constant inflammatory stimuli the initial healing 
response can cause excessive fibrosis and lead to tissue and organ dysfunction 
(Kalluri and Weinberg 2009). Upon injury, immune cells, most prominently 
macrophages (Kalluri and Weinberg 2009), infiltrate the site of injury and release 
pro-inflammatory cytokines such as IL-1β, Tumor Necrosis Factor α, and IL-6 
along with the pro-fibrotic cytokine TGFβ (Mirza and Koh 2015). These 
macrophages also secrete chemo-attractant cytokines and matrix degrading 
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enzymes (MMP2/9) that facilitate further immune cell infiltration, release of 
cytokines such as TGFβ, and inflammation(Strutz, Zeisberg et al. 2002, Kalluri 
and Weinberg 2009). High TGFβ signaling has been shown to be critical in the 
development of most forms of fibrosis (Branton and Kopp 1999). 
Past attempts to use TGFβ antagonists to treat EMT-associated diseases 
have found that this class of drugs had severe side effects, probably caused by 
the fact that, in addition to its role in fibrosis, TGFβ signaling also serves other 
important functions such as growth inhibition (Laiho, DeCaprio et al. 1990), 
suppression of inflammation (Sheng, Chen et al. 2015), and hematopoiesis 
(Fortunel, Hatzfeld et al. 2000). 
Our data has repeatedly shown that inhibition of calpain activity does not 
affect early TGFβ signaling events (Figure 2,3,11), but can potently inhibit TGFβ-
induced expression of fibrosis-associated genes (Figure 5). We were initially 
surprised to learn that TGFβ-induced EMT utilizes calpain isoforms that are not 
normally expressed in the relevant progenitor cell types, but rather are rapidly 
and potently induced by TGFβ. In retrospect this appears to be a remarkably 
elegant and efficient strategy for nature to tightly regulate a process that is 
occasionally necessary and productive (as in the case of wound healing), but can 
in often prove deleterious if left unchecked. Restriction of this EMT-promoting 
activity to calpains that are uniquely expressed in response to an overt fibrogenic 
stimulus such as TGFβ prevents activation of the EMT pathway in response to 
other physiological stimuli that result in increased intracellular Ca2+ concentration 
and normally result in activation of other constitutively expressed calpains. In this 
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light, it may also make sense that Capn9 and Capns2 are normally only highly 
expressed in the gastrointestinal tract and skin (Figure 19), respectively, two 
tissues that are subject to excessive wear-and-tear and show a remarkable 
capacity for rapid repair and regeneration. 
Consistent with the notion that CAPN9 and CAPNS2 serve specialized 
functions in the context of EMT and fibrosis, the Capn9-/- mouse is able to fully 
develop and is physiologically normal (Hata, Abe et al. 2010), yet is incredibly 
resistant to bleomycin-induced lung fibrosis compared to wild-type mice (Figure 
26). Based on these data, we believe that calpain inhibitors designed to 
specifically suppress activity of CAPN9/CAPNS2 would be a potentially ideal 
class of drugs for targeting fibrosis-associated EMT exclusively. Side effects 
would be limited because such a drug would not affect the physiological functions 
of TGFβ or the enzymatic activity of constitutively expressed calpains. 
 Myofibroblasts have been firmly implicated in the majority of fibrotic 
conditions (Estes, Vande Berg et al. 1994). Various cell types can undergo 
mesenchymal transition to give rise to pro-fibrotic myofibroblasts (Tanjore, Xu et 
al. 2009, Hashimoto, Phan et al. 2010, Chen, Zhang et al. 2013). Importantly, we 
have shown that calpain inhibitors are able to inhibit myofibroblast formation from 
several major sources, including epithelial cells (Figure 2,3,11), fibroblasts 
(Figure 8), and endothelial cells (Figure 13, Figure 20). Our data also show that 
calpain activity is necessary to maintain a myofibroblast state, suggesting that a 
targeted calpain inhibitor could be curative for patients in which fibrosis is already 
established. 
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Our data suggest that during TGFβ-induced EMT, the pro-fibrotic activity 
of CAPN9/CAPNS2 is at least in part mediated by activation of the phosphatase 
calcineurin. Although this might suggest that calcineurin inhibitors (e.g. 
cyclosporin, tacrolimus) might be used as anti-fibrotic drugs, the severe side 
effects associated with these drugs, such as hypertension and renal toxicity, 
make their use for the treatment of fibrosis less desireable (Morton and Powell 
2000). In a small clinical study, 13 scleroderma patients were given cyclosporine 
to treat skin fibrosis and half noticed a small improvement in skin thickness, but 
side effects became so severe that it led to 12 of the patients withdrawing from 
the trial (Morton and Powell 2000). These drugs have been shown to inhibit a 
constitutively active form of calcineurin (O'Keefe, Tamura et al. 1992) that is very 
similar to that generated upon cleavage by calpains. Their modest but dose-
limited effect on skin fibrosis (Morton and Powell 2000) suggests that a calpain 
inhibitor could have greater efficacy to treat fibrotic conditions due to its predicted 
lower toxicity. 
Based on the restricted expression of CAPN9/CAPNS2 in the 
gastrointestinal tract and skin (Figure 19), we believe that a drug targeting 
CAPN9/CAPNS2 would not suppress the immune system. In addition, Capn9-/- 
mice do not exhibit an immuno-compromised phenotype (Hata, Abe et al. 2010).  
 Currently, there are no effective therapies to treat the numerous fibrotic 
disorders that affect a significant number of the world’s population. Our work has 
identified a new pathway that is critically involved in a cellular mechanism linked 
to numerous disease processes and possesses most of the characteristics 
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required in an ideal drug target. It is our hope that this work will lead to the 
development of safer therapeutic drugs for the treatment of fibrosis and other 
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